Gefitinib is a targeted therapy used primarily to treat non-small cell lung cancer (NSCLC) in patients with specific epidermal growth factor receptor (EGFR) mutations. It works by blocking the signals that cancer cells use to grow and divide, offering a more precise and effective treatment compared to traditional chemotherapy.
Taken orally, Gefitinib is typically prescribed to patients whose cancer has advanced or spread, and who test positive for EGFR mutations. It has shown significant benefits in improving progression-free survival and quality of life, with fewer side effects than conventional cancer therapies.
With the growing demand for accessible cancer treatments, India has become a global hub for high-quality generics. A leading gefitinib tablet manufacturer in India (https://www.specialitymedz.com/product/gefitinib-manufacturer/) ensures that this life-saving medication is available at affordable prices without compromising on quality. These manufacturers play a vital role in expanding global access to essential oncology treatments.